CD274 and hepatocellular carcinoma: For example, some trials, such as KEYNOTE-224 and CheckMate-459, demonstrated improved outcomes in PD-L1-positive HCC patients, whereas CheckMate-040 reported no significant correlation between PD-L1 levels and ICI efficacy.